Previous 10 | Next 10 |
A surge in psychedelic research in recent years has revealed something quite interesting: several psychedelic drugs are capable of alleviating symptoms of mental disorders with relatively few side effects. Dubbed the psychedelic renaissance , this movement has seen dozens of researchers across...
2023-05-23 17:14:55 ET Gainers: Reata Pharmaceuticals ( RETA ) +10% . Urban Outfitters ( URBN ) +7% . COMPASS Pathways ( CMPS ) +6% . Stitch Fix ( SFIX ) +5% . TScan Therapeutics ( TCRX ) +4% . Losers: PTC The...
Interest in psychedelics has increased greatly in the last decade or so, as new studies into the treatment of various mental health conditions using these drugs are conducted. As more positive benefits are discovered, we have seen changes to laws that previously prohibited access to the use of ...
2023-05-13 10:17:09 ET COMPASS Pathways plc (CMPS) Q1 2023 Earnings Conference Call May 11, 2023 08:00 AM ET Company Participants Steve Schultz - Senior Vice President of Investor Relations Kabir Nath - Chief Executive Officer Guy Goodwin - Chief Medical Officer ...
2023-05-11 12:30:37 ET Image source: The Motley Fool. Compass Pathways Plc (NASDAQ: CMPS) Q1 2023 Earnings Call May 11, 2023 , 8:00 a.m. ET Operator Continue reading For further details see: Compass Pathways Plc (CMPS) Q1 2023 Earnings Ca...
2023-05-11 07:02:59 ET COMPASS Pathways ADS press release ( NASDAQ: CMPS ): Q1 GAAP EPS of -$0.57 beats by $0.12 . Cash and cash equivalents were $117.1 million as of 31 March 2023, compared with $143.2 million as of 31 December 2022. Additional $26.9 million net c...
LONDON, May 11, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, reported its financial results for the first quarter 2023 and gave an up...
LONDON, May 03, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial results for the first quarter 2023, and provide an upda...
LONDON and SAN JOSE, Calif., May 02, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS) (COMPASS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, and MAPS Public Benefit Corporation (MAPS PBC), a clinical-stage compan...
Numerous studies have shown that psychedelics possess a range of therapeutic benefits that may be useful in treating various conditions. For instance, one study found that administering psilocybin reduced anxiety and depression in patients with cancer. This research also intersects with arti...
News, Short Squeeze, Breakout and More Instantly...
LONDON, July 24, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial results for the second quarter 2024 ending June 30, 2024, a...
New research has determined that psilocybin may impact the brain. Psilocybin is the primary psychoactive compound found in hallucinogenic mushrooms. When ingested, it distorts an individual’s perception of time, among other changes. Researchers have observed that in animals, psilocyb...